Aim To evaluate the effect of rosuvastatin medication with different doses on serum level of soluble lectin-like oxidized low-density lipoprotein receptor-1（sLOX-1）in patients with acute coronary syndrome（ACS）. Methods Patients（n80）with ACS were randomly assigned into rosuvastatin 10 mg group（40 mg loading dose and 10 mg/d,RSV10 group,n40）and rosuvastatin 5 mg group（5 mg/d, RSV5 group,n40）. All patients were accepted based on the clinical situation, including coronary revascularization, and aspirin, clopidogrel hydrogen, tirofiban, low molecular weight heparin, ACEI/ARB, β-blockers, calcium channel blockers, nitric acid esters drugs, diuretics and other basic drugs. Major adverse cardiac events（MACE）were observed during hospitalization, monitoring adverse drug reactions. Serum sLOX-1 levels of immediate admission on the third day were determinated using enzyme-linked immunosorbent assay and were compared between groups. Results Baseline characteristics were nearly identical in both groups. The density of sLOX-1 on the third day during hospitalization is 290.03±141.43 ng/L in RSV10 group, which remarkablely decreases in comparison with the value of 397.86±170.61 ng/L on admission. Reduce of the rate is 27.1%（t4.625，P<0.001）；The density of sLOX-1 in the third day during hospitalization is 300.03±135.31 ng/L in RSV5 group. The value of sLOX-1 declined significantly as well compared with 385.66±154.39 ng/L on admission，and the reduction is 22.2%（t3.329，P<0.05）； The comparison of the sLOX-1 density between the two groups on admission has no significance（t－0.335，P0.739） The reduction has no significance as well between the two groups（t－0.639，P0.525）. There is no difference in leukocyke count and neutrophil percentage，which actually decreased after treatment in both groups and RSV10 group decreased more significantly（t2.254，P<0.05）； The rate of MACE during hospitalization in RSV10 group is lower than RSV5 group（χ²4.588，P<0.05） There is no adverse drug recation during hospitalization in both two groups. Conclusion In clinical practice,early rosuvastatin treatment could significantly decrease the serum density of sLOX-1 in patients with ACS,obviously. Besides, the effect showed no dose dependent. Loading-dose and mild moderate-dose statin,which is relatively safe, could reduce the incidence of MACE during hospitalization.